PharmaShots | Incisive News in 3 Shots

Subscribe Now

follicular lymphoma

$Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021$

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

June 3, 2021

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

March 8, 2021

BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

November 5, 2020

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

August 4, 2020

$Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma$

Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma

July 14, 2020

Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma

Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymph...

April 22, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us